The Crohn’s and Colitis Foundation of America launches new Web site
NEW YORK The Crohn’s and Colitis Foundation of America recently launched its updated Web site to usher in the 2010 Walk season comprising more than 100 walks nationwide.
The Foundation reached a new plateau with new interactive features such as a blog, downloadable banners and widgets, and tips and tools for fundraising to support the walks that raise much-needed awareness of and funds for the 1.4 million Americans living with Crohn’s disease and ulcerative colitis, both chronic digestive diseases.
“It’s very important that we create an environment that fosters awareness and support for our Walks, while making the job a little easier for those participating,” stated Cassidy Richards, National Event Director for the Foundation. “One way we’re doing that is with our new banners and widgets in different sizes that people can add to their social networking sites like Facebook.”
The banners and widgets can also be added to participants’ blogs, personal web sites, and on e-mails to friends to help get the word out about Take Steps. Available on the site’s new Spread the Word section, these tools are part of the Foundation’s efforts to help walkers show their support and get others to join Take Steps.
The new Web site also offers helpful suggestions on how to organize fundraisers at school or at work even during these trying economic times. It also encourages people to join a team, make a donation, or take part in volunteer activities through the site’s Get Involved feature.
The upcoming season kicks-off in spring 2010 and will continue into the summer in cities throughout the country.
Ulcerative colitis treatment reduces need for surgery by almost half, study suggests
NEW YORK A new study led by Mayo Clinic researchers found that ulcerative colitis patients had a 41% reduction in colectomy when treated with infliximab for one year, according to a study published in the October 2009 issue of Gastroenterology.
Ulcerative colitis, an inflammatory bowel disease that causes chronic inflammation of the colon, is characterized by abdominal pain and diarrhea. Like Crohn’s disease, another common IBD, ulcerative colitis can be debilitating and often lead to colectomy, or surgical removal of the colon.
In the study, 728 patients received placebo or infliximab (5 or 10 mg/kg) for 46 weeks and were monitored for hospitalization or surgical outcomes. Eighty-seven percent had complete follow-up for the endpoint of whether or not they had colectomy, while the remaining 13% of patients had follow-up for less then a year, with a median follow-up of 6.2 months in these patients. The research showed that treatment with infliximab at zero, two, six and then every 8 weeks, reduced the incidence of colectomy through 54 weeks by 41% in outpatients with moderately-to-severe active ulcerative colitis.
Infliximab is an artificial antibody that works by blocking tumor necrosis factor alpha, a chemical messenger and a key part of the immune reaction. Infliximab blocks the action of TNF alpha by preventing it from binding to its receptor in the cell.
“Our purpose in this study was to see if the use of infliximab for ulcerative colitis would reduce the need for surgery,” said William Sandborn, M.D., a Mayo Clinic gastroenterologist and lead author of the study. “We found that treatment with infliximab reduced the need for colectomy by 41% compared to patients treated with placebo.”
Previous research has shown that infliximab therapy induced clinical remission and bowel healing for colitis patients. This new research provides more information and options for patients struggling with this difficult disease, explained Sandborn.
New report projects 12.6% increase of probiotics market
WILMINGTON, Del. The food and beverage practice at MarketsandMarkets projected the global probiotics market to be worth $32.6 billion by 2014, growing at a compound annual growth rate of 12.6% from 2009 to 2014 during its “Analyst Briefing Presentation on the Global Probiotic Market” held Tuesday.
Europe and Asia are expected to account for nearly 42% and 30% of the total revenues, respectively, in 2014. The U.S. market has opened up to these products in the recent past and is expected to grow at a CAGR of 17% from 2009 to 2014, the biggest contributor being probiotic cultured drinks followed by probiotic yogurts. Though the market base of probiotic products is comparatively lesser in the United States, the market is expected to grow at a rate of almost 14% in the same period driven by the large-scale acceptance of probiotic yogurts, probiotic cultured drinks and probiotic dietary supplements.
“The early movers in the industry will benefit in terms of market share but it is important that they focus on innovating probiotic strains that are more efficient in terms of survivability in harsh conditions and stability and are supported by competitively-priced production technologies,” the company stated. “In addition, garnering faith of the consumers by making substantiated and legitimate assertions in terms of health benefits will profit the market in future.”